Leaflet LEVOMEPROMAZIN ASPIRE 25mg tablets


Indicated for: schizophrenia; bipolar disorder

Route of administration: oral

Substance: levomepromazine (antipsychotic)

ATC: N05AA02 (Nervous system | Antipsychotics | Phenothiazines with aliphatic side-chain)

Levomepromazine is an antipsychotic medication used to treat schizophrenia and other psychotic disorders. It is also used to alleviate symptoms of severe agitation, anxiety, or insomnia.

This medication belongs to the class of typical antipsychotics and works by blocking dopamine receptors in the brain, which helps reduce psychotic symptoms such as hallucinations and delusions.

Levomepromazine is administered orally or by injection, and the dosage is adjusted based on the severity of symptoms and the patient's response. Side effects may include drowsiness, dizziness, dry mouth, weight gain, or low blood pressure.

Patients should be regularly monitored by their doctor, especially if they have other medical conditions or are taking other medications. Pregnant or breastfeeding women should consult a specialist before using this medication.

General data about LEVOMEPROMAZIN ASPIRE 25mg

  • Substance: levomepromazine
  • Date of last drug list: 01-05-2026
  • Commercial code: W71817001
  • Concentration: 25mg
  • Pharmaceutical form: tablets
  • Quantity: 1
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: PHARMADOX HEALTHCARE LTD. - MALTA
  • Holder: ASPIRE PHARMA (MALTA) LIMITED - MALTA
  • Number: 16543/2026/01
  • Shelf life: 2 years

Concentrations available for levomepromazine

  • 100mg
  • 25mg